Ewa Carrier is a distinguished physician and scientist currently serving as the Director of Clinical Development and Medical Affairs at Boehringer Ingelheim, where she leverages her extensive expertise in stem cell transplantation, regenerative medicine, and hematology to drive innovative therapeutic solutions. With a robust background...
Ewa Carrier is a distinguished physician and scientist currently serving as the Director of Clinical Development and Medical Affairs at Boehringer Ingelheim, where she leverages her extensive expertise in stem cell transplantation, regenerative medicine, and hematology to drive innovative therapeutic solutions. With a robust background in global clinical trials and product development, Ewa has been instrumental in advancing the company's portfolio, particularly in the realm of hematological malignancies. Her leadership in the clinical development of Volasertib, a first-in-class Plk inhibitor that received breakthrough therapy designation for acute myeloid leukemia (AML) in June 2013, exemplifies her commitment to addressing unmet medical needs.
Ewa's work encompasses a wide array of key projects focused on enhancing the clinical applications of embryonic, hematopoietic, and mesenchymal stem cells. She is particularly adept at optimizing the homing mechanisms of these cells through innovative techniques such as fucosylation, which has significant implications for cord blood and mesenchymal stem cell therapies. Her research in cancer vaccine development further underscores her dedication to pioneering treatments that can improve patient outcomes in oncology.
In her role, Ewa collaborates closely with cross-functional teams, ensuring compliance with FDA regulations and GCP standards while navigating the complexities of biotechnology and clinical research organizations (CROs). Her proficiency in medical writing and her deep understanding of infectious diseases and pediatrics enhance her ability to communicate complex scientific concepts effectively to diverse stakeholders. Ewa Carrier's multifaceted expertise positions her as a leader in the field, driving forward-thinking strategies that are shaping the future of regenerative medicine and hematology at Boehringer Ingelheim.
